Combinatorial Protocols.

Field tuned to the indication. Bioregulator tuned to the cell.

Layer designations refer to the four-layer model. Field parameters describe the operating envelope for the indication. The bioregulator column lists the Khavinson-lineage short peptides selected for synergistic action with the field protocol.

Why pairing matters.

Bioregulators alone instruct the cell what to make. They are pure chemistry — they bind to a target, they activate or inhibit a pathway, and they diffuse wherever the bloodstream takes them. They have no spatial control.

Pulsed electromagnetic fields alone instruct the cell where it is and when to act. They open ion channels, prime the membrane, shift the bioelectric pattern, and signal the mitochondria — but they have no cargo. The cell makes whatever its current transcription program directs it to make.

The combination is synergy rather than addition. A primed cell takes up bioregulator more efficiently. The dose-response curve shifts, side-effect profiles narrow, and the same outcome is achieved at lower bioregulator concentrations. The field supplies the spatial dimension bioregulators cannot, and the bioregulator supplies the regulatory specificity the field cannot. This is the basis for the method-of-use claims that anchor the discipline.

New indications neither modality reaches alone.

Bone non-union is a pulsed-field indication. Senescent cell rejuvenation is approached by bioregulators. Senescence-resistant fracture healing in osteoporotic patients is the combination — and it is a new indication, with its own clinical pathway, its own claim set, and its own market. The same pattern holds for diabetic wound care, peripheral nerve regeneration, articular cartilage restoration, and pineal-axis longevity. Five indications. Five claim sets. One platform.